Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Last trade$25.86
Day change-$0.59 (-2.23%)
Day range$25.56 – $26.95
Volume273,259
Market cap$1.85B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.85B
Price / earnings
42.83×
Price / book
7.18×
Price / sales
6.97×
EV / sales
6.6×
EV / EBITDA
35.64×
Profitability
Earnings per share
$0.62
Return on assets
3.68%
Return on equity
16.77%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.3×
Quick ratio
3.3×
Cash ratio
0.62×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$112.83M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ZYME, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$256.46M
$4.59M
$2.41M
$2.52M
$27.61M
$48.73M
$27.11M
$31.03M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$256.46M
$4.59M
$2.41M
$2.52M
$27.61M
$48.73M
$27.11M
$31.03M
Selling, general and administrative
$42.74M
$19.34M
$15.07M
$15.43M
$14.15M
$14.95M
$16.99M
$16.19M
Research and development
$36.13M
$27.44M
$34.46M
$31.24M
$35.58M
$34.45M
$35.74M
$37.06M
Total operating expenses
$78.86M
$46.77M
$49.53M
$46.67M
$49.72M
$49.4M
$52.72M
$53.25M
Operating income
$177.6M
-$42.18M
-$47.12M
-$44.15M
-$22.11M
-$674K
-$25.61M
-$22.22M
Interest expense
-$6.69M
-$6.6M
$645K
$0
$0
$0
$3.42M
$0
Income before taxes
$173.25M
-$45.29M
-$46.35M
-$41.48M
-$18.27M
$2.13M
-$22.14M
-$17.79M
Income taxes
-$452K
-$273K
-$2.19M
-$270K
$1.34M
-$186K
$496K
$5.72M
Net income
$173.7M
-$45.02M
-$44.16M
-$41.21M
-$19.6M
$2.32M
-$22.64M
-$23.51M
Net income attributable to common shareholders
$173.7M
-$45.02M
-$44.16M
-$41.21M
-$19.6M
$2.32M
-$22.64M
-$23.51M
EBITDA
$179.32M
-$41.05M
-$45.98M
-$43.07M
-$20.56M
$1.82M
-$23.02M
-$19.22M
Basic earnings per share
$2.43
-$0.62
-$0.59
-$0.55
-$0.26
$0.03
-$0.30
-$0.31
Diluted earnings per share
$2.28
-$0.62
-$0.59
-$0.56
-$0.26
$0.03
-$0.30
-$0.31
Recent news
Company coverage with links to the original publishers.
Zymeworks Inc. reported Q3 2026 earnings of $2.28 per share, missing the consensus estimate of $2.40 per share by 5%, though revenues of $256.46 million exceeded expectations by 2.72%. The company has failed to surpass consensus EPS estimates over the last four quarters. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market. The Medical - Biomedical and Genetics industry ranks in the top 43% of Zacks industries.
Alvotech is expected to report a quarterly loss of $0.01 per share with revenues of $137.09 million (up 20.4% YoY) on November 11, 2026. Despite a positive Earnings ESP of +250%, the stock's Zacks Rank #4 (Sell) rating makes it difficult to predict an earnings beat. The company has failed to beat consensus EPS estimates in the last four quarters, with the most recent quarter delivering an -83.33% surprise.
Zymeworks Inc. (ZYME) is expected to report Q3 2026 earnings of $2.40 per share with revenues of $249.68 million, representing significant year-over-year growth. However, the company has a negative Earnings ESP of -0.52% with a Zacks Rank #3 (Hold), making it difficult to predict an earnings beat. The company has a poor track record, beating consensus estimates only once in the last four quarters.
Zymeworks presented Phase 1 data for ZW191, a folate receptor alpha-targeting antibody-drug conjugate, showing a confirmed objective response rate of 64.5% at the 6.4 mg/kg dose in heavily pretreated patients with platinum-resistant ovarian cancer. The drug demonstrated meaningful activity across all FRα expression levels with a favorable tolerability profile, particularly at the lower dose, supporting continued clinical development.
Zymeworks announced a global license and collaboration agreement with Roche for ZW209, a trispecific T cell engager targeting DLL3. Zymeworks will receive $55 million upfront and $40 million upon Phase 1b initiation, with potential for up to $718 million in additional milestone payments and tiered royalties on future net sales. Zymeworks will conduct the Phase 1a trial while Roche funds it and handles subsequent development and commercialization.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.